Dusseldorf - Delayed Quote EUR
Peijia Medical Ltd (4WO.DU)
0.6200
+0.0300
+(5.08%)
At close: May 2 at 7:30:23 PM GMT+2
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
615,483
615,483
441,126
250,833
136,534
Cost of Revenue
181,862
181,862
115,756
74,632
40,880
Gross Profit
433,621
433,621
325,370
176,201
95,654
Operating Expense
663,925
663,925
741,198
727,925
645,256
Operating Income
-230,304
-230,304
-415,828
-551,724
-549,602
Net Non Operating Interest Income Expense
17,744
17,744
39,259
44,313
24,585
Pretax Income
-221,601
-221,601
-391,501
-398,235
-574,216
Tax Provision
6,891
6,891
1,052
9,574
--
Net Income Common Stockholders
-226,576
-226,576
-392,525
-407,809
-574,216
Diluted NI Available to Com Stockholders
-226,576
-226,576
-392,525
-407,809
-574,216
Basic EPS
-0.34
--
-0.58
-0.61
-0.86
Diluted EPS
-0.34
--
-0.58
-0.61
-0.86
Basic Average Shares
669,488
--
679,275
673,160
661,656
Diluted Average Shares
669,488
--
679,275
673,160
661,656
Total Operating Income as Reported
--
--
-430,760
-442,548
-598,801
Total Expenses
845,787
845,787
856,954
802,557
686,136
Net Income from Continuing & Discontinued Operation
-226,576
-226,576
-392,525
-407,809
-574,216
Normalized Income
-211,444
-211,444
-374,655.5000
-395,231.5000
-574,678
Interest Income
22,480
22,480
39,437
46,629
24,771
Interest Expense
4,736
4,736
178
2,316
186
Net Interest Income
17,744
17,744
39,259
44,313
24,585
EBIT
-216,865
-216,865
-391,323
-395,919
-574,030
EBITDA
-157,809
-157,809
-348,521
-359,905
-546,544
Reconciled Cost of Revenue
181,862
181,862
115,756
74,632
40,880
Reconciled Depreciation
59,056
59,056
42,802
36,014
27,486
Net Income from Continuing Operation Net Minority Interest
-226,576
-226,576
-392,525
-407,809
-574,216
Total Unusual Items Excluding Goodwill
-20,176
-20,176
-23,826
-16,770
462
Total Unusual Items
-20,176
-20,176
-23,826
-16,770
462
Normalized EBITDA
-137,633
-137,633
-324,695
-343,135
-547,006
Tax Rate for Calcs
0.0003
0.0003
0.0003
0.0003
--
Tax Effect of Unusual Items
-5,044
-5,044
-5,956.5000
-4,192.5000
--
12/31/2021 - 1/9/2025
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
Upgrade